ݔѪt(y)W(xu)g(sh)ZhZ(du)ձ
l(f)r(sh)g:2020-10-22 Դ: Y(ji) c(din)
hZ ݔѪt(y)W(xu)g(sh)Z(du)ձ
ꑣ (ni)أ
_(ti) T A
ABO blood group determination ABO ѪͶ ABO Ѫͷ ABO ѪͶ ABOѪʹ_ absorption and elution test շɢԇ(yn) ?jng)_ԇ(yn) շɢԇ(yn) ጳyԇ acute hypervolemic hemodilution; AHH ԸѪҺϡ ԸѪѪҺϡ ԸѪҺϡ ԸѪѪҺϡ acute normovolemic hemodilution; ANH ԵѪҺϡ ԵѪѪҺϡ ԵѪҺϡ ԵѪҺϡ adverse event ¼ ¼ ¼ ¹ allelic resolution typing λˮƽ o λˮƽ (du)(yng)ˮƽ alloimmunization ͬNw w w w altruistic blood donation ԫI(xin)Ѫ ԾѪ ԾѪ ԾѪ antibody screening wY wYz wYz wYz apheresis blood component βѪҺɷ xg(sh)ѪҺɷ ΒѪҺɷ ɷѪѪҺɷ Apheresis β xg(sh) Β ɷݾѪ audit criteria ˜(zhn)t ˘(bio)(zhn) ˜(zhn)t ˜(zhn)t autologous transfusion wݔѪ wѪ wݔѪ Ѫ B
blood cold chain ѪҺ ѪҺ ѪҺ ѪҺ blood donation adverse reaction I(xin)Ѫ(yng) Ѫ(yng) Ѫ(yng) Ѫ(yng) blood donation times per thousand population ǧ˿ګI(xin)Ѫ˴ ÿǧ˿ھѪ˴ ǧ˿ھѪ˴ ǧ˿ھѪ˴ blood donation I(xin)Ѫ Ѫ Ѫ Ѫ blood donor I(xin)Ѫ Ѫ Ѫ Ѫʿ blood establishment computer system ѪվϢϵy(tng) ѪC(j)(gu)YӍϵy(tng) ѪҺYӍϵy(tng) ѪXϵy(tng) blood group typing Ѫb Ѫͷ Ѫb Ѫͷ blood quality ѪҺ|(zh) ѪҺƷ|(zh) ѪҺ|(zh) ѪҺ|(zh) blood screening test ѪҺYԇ(yn) ѪҺYzԇ(yn) ѪҺYz(yn) ѪҺYzyԇ blood-borne occupational exposure ѪԴI(y)¶ ѪҺȾԼI(y)¶ ѪԴI(y)¶ ѪԴI(y)| blood-donor care I(xin)Ѫo(h) Ѫo(h) ѪP(gun)o(h) Ѫʿo(h) C
cell grouping (x) (x) (x) (x) cell salvage Ѫ(x) ѪҺ(x) Ѫ(x) (x) clinical transfusion medicine RݔѪW(xu) RݔѪt(y)W(xu) RݔѪt(y)W(xu) RݔѪt(y)W(xu) closed system ]ϵy(tng) ]ϵy(tng) ]ϵy(tng) ܷϵy(tng) compatibility test ԇ(yn) ԇ(yn) ԙz(yn) Ԝyԇ complement-dependent lymphocytotoxicity test; CDC a(b)wهԼ(x)ԇ(yn) a(b)wهܰԇ(yn) a(b)wهԼ(x)ԇ(yn) a(b)wهܰͼ(x)(yng)yԇ complication related to blood donation I(xin)ѪP(gun)l(f)Y ѪP(gun)l(f)Y ѪP(gun)l(f)Y ѪP(gun)l(f)Y confirmatory test _Cԇ(yn) _J(rn)ԇ(yn) _Cz(yn) _J(rn)yԇ copper sulfate method ~ ~ ~ ~yԇ corrected count increment; CCI ѪСӋ(j)(sh)Уֵ ѪСӋ(j)(sh)УӔ(sh) ݔעѪСָ(sh) Уָ(sh) crossmatch Ѫ Ѫ Ѫ Ѫ D
department of transfusion medicine t(y)ԺݔѪ ݔѪt(y)W(xu) t(y)ԺݔѪ o diversion pouch ·D(zhun)ƴ ӱռ ӱռ donor (informed) consent I(xin)Ѫ֪ͬ Ѫ֪ͬ Ѫ֪ͬ Ѫʿ@֪(hu)ͬ donor deferral I(xin)Ѫ ѪѪ Ѫ Ѫ donor identification I(xin)Ѫߴ_J(rn) Ѫ˴_J(rn) Ѫݴ_J(rn) Ѫʿݴ_J(rn) donor quarantine I(xin)Ѫ Ѫ˸x o Ѫʿx donor reentry I(xin)Ѫߚw(du) Ѫپ ѪپѪ ѪʿپѪ donor I(xin)Ѫ Ѫ Ѫ Ѫ E
electronic crossmatch ӽѪ ӽѪ ӽѪ XѪ elite controller Ӣ Ӣ o o emerging infection °l(f)Ⱦ °l(f)Ⱦ °l(f)Ⱦ °l(f)Ⱦ event ¼ ¼ ¼ ¼¹ external quality assessment; EQA g|(zh)u(png)r(ji) ⲿƷ|(zh)u(png) ⲿ|(zh)u(png)r(ji) |(zh)u(png) F
febrile non-hemolytic transfusion reaction; FNHTR Ѫl(f)ᷴ(yng) Ѫl(f)(yng) Ѫl(f)ᷴ(yng) Ѫl(f)(yng) first-time donor ΫI(xin)Ѫ ξѪ ״ξѪ ξѪ״ξѪ
forward type o freezing ك ٱ fundamental
transfusion
medicine A(ch)ݔѪW(xu) A(ch)ݔѪt(y)W(xu) A(ch)ݔѪt(y)W(xu) A(ch)ݔѪt(y)W(xu) G
grey zone ҅^(q) o ҅^(q) ɫ؎ H
haemovigilance; HV ѪҺȫO(jin)y ѪҺȫO(jin)y ѪҺA(y)ϵy(tng) ѪҺȫA(y)ϵy(tng) hematocrit; Hct t(x) Ѫ t(x) o hematology analyzer method ѪҺxzy ѪҺxzy ѪҺxzy ѪҺx Hemoglobin; Hb Ѫt Ѫt Ѫt ѪtػѪt hemoglobin test strip colorimetric assay Ѫtԇlɫ Ѫtԇlɫ Ѫtԇlɫ o high resolution typing ߷ֱʷ ߽ȷ ߷ֱʷ ߽ histocompatibility matching M M䌦(du) M M human leucocyte antigen; HLA (x)ԭ Ѫԭ (x)ԭ Ѫԭ I
immediate hemolytic transfusion reaction; IHTR ٰl(f)ѪݔѪ(yng) l(f)ѪݔѪ(yng) ѪݔѪ(yng) ѪݔѪ(yng) incidence rate ¸Ⱦ l(f) ¸Ⱦ l(f) initial test ԇ(yn) ԇ(yn) Ιz(yn) yԇ inter-instrument comparison xgȌ(du) xgȌ(du) xgȌ(du) x֮g^ inter-laboratory comparison (sh)(yn)gȌ(du) (sh)(yn)gȌ(du) (yn)gȌ(du) (sh)(yn)֮g^ internal audit (ni)|(zh) (ni) (ni)|(zh) (ni) internal quality control; IQC ҃(ni)|(zh) ҃(ni)Ʒ (ni)|(zh) (ni)Ʒ|(zh) inter-reagent comparison ԇȌ(du) ԇȌ(du) ԇȌ(du) ԇ֮g^ inter-regional donor quarantine ^(q)(lin) o o o inventory management ѪҺ ѪҺ irradiation ݗ
ݗ(չ)
ݗ ݗ L
laboratory information management system (sh)(yn)Ϣϵy(tng) (sh)(yn)YӍϵy(tng) (yn)YӍϵy(tng) (sh)(yn)YӍϵy(tng)
leukocyte reduction ȥ(x) p ȥ(x) ȥѪѪ Look back low resolution typing ͷֱʷ ͽȶ ͷֱʷ o lymphocyte microcytotoxicity test; LCT ܰͼ(x)ԇ(yn) ܰԇ(yn) ܰͼ(x)ԇ(yn) o M
major crossmatch (c)Ѫ (c)Ѫ ҪѪ management review u(png) 팏 u(png) u(png) minor crossmatch (c)Ѫ С (c)Ѫ ҪѪ mixed lymphocyte culture; MLC ܰͼ(x)B(yng) ܰB(yng) ܰͼ(x)B(yng) o mixed lymphocyte reaction; MLR ܰͼ(x)(yng) ܰϷ(yng) ܰͼ(x)(yng) o N
natural antibody Ȼw Ȼw Ȼw Ȼw naturally occurring antibody Ȼw Ȼa(chn)w Ȼa(chn)Ŀw Ȼa(chn)w near miss ¼ Ee(cu)ʧ U(xin)ʧ¼ o non-reactive o(yng) o(yng) o(yng) o(yng) non-remunerated voluntary blood donor ԸoI(xin)Ѫ (yun)oѪ (yun)oѪ o(yun)Ѫ nucleic acid testing yield; NAT yield zy z o yԇ O
occult HBV infection; OBI [ײȾ [ B ײȾ [ײȾ [ one-way mixed lymphocyte culture ܰͼ(x)B(yng) ܰB(yng) ܰͼ(x)B(yng) o P
panel cells V(x) (x)M V(x) o panel reactive antibody; PRA wV(x)(yng) (x)Mw(yng) wV(x)(yng) o para-Bombay phenotype I IѪ I o pathogen inactivation; PI ԭw ԭ ԭw ԭ pathogen reduction; PR ԭwȥ ԭp ԭwȥ ԭ patient blood management; PBM ѪҺ ѪҺ ѪҺ Ѫ plasma exchange Ѫ{ÓQ Ѫ{ÓQ Ѫ{ÓQ QѪ{ platelet count; PLT ѪСӋ(j)(sh) ѪСӋ(j)(sh) ѪСӋ(j)(sh) ѪС唵(sh)
platelet-rich plasma method ѪСѪ{ ѪСѪ{ ѪСѪ{ preoperative autologous blood donation; PAD g(sh)ǰwѪ(ch) g(sh)ǰwѪ g(sh)ǰwѪ g(sh)ǰѪ pretransfusion testing ݔѪǰzy ݔѪǰz(yn) ݔѪǰz(yn) ݔѪǰz(yn) prevalence rate ʢ proficiency testing; PT (sh)(yn)(yn)C ԇ(yn) (yn)(yn)C yԇ Q
quality objective |(zh)Ŀ(bio) Ʒ|(zh)Ŀ(bio) |(zh)Ŀ(bio) |(zh)Ŀ(bio) quality assurance |(zh)C Ʒ|(zh)C |(zh)C |(zh)^ quality control |(zh) Ʒ|(zh) |(zh) |(zh) R
reactive (yng) (yng) (yng) (yng) recalcification of plasma Ѫ{(f)} Ѫ{} Ѫ{(f)} Ѫ{} recipient (informed) consent Ѫ֪ͬ Ѫ֪ͬ Ѫ֪ͬ Ѫ߫@֪(hu)ͬ recipient identification Ѫߴ_J(rn) Ѫߴ_J(rn) Ѫݴ_J(rn) Ѫݴ_J(rn) red cell group system t(x)Ѫϵy(tng) tѪѪϵy(tng) t(x)Ѫϵy(tng) tѪϵy(tng) red cell reagent panel ԇt(x)M tѪԇM ԇt(x)M o regular donor ګI(xin)Ѫ ھѪ Ҏ(gu)Ѫ aѪھѪ repeat donor ؏(f)I(xin)Ѫ }Ѫ }Ѫ }Ѫ residual risk L(fng)U(xin) NL(fng)U(xin) NL(fng)U(xin) NL(fng)U(xin) reverse type o RhD initial typing RhD Ѫͳz RhD z RhD Ѫͳz RhD z(yn) RhD typing RhD Ѫb RhD RhD Ѫb RhD Ѫ͙z(yn) confirmatory test
for
Rh
negative Rh Դ_J(rn)
Rh Դ_J(rn)
Rh Դ_J(rn) Rh Դ_J(rn)yԇ risk behavior L(fng)U(xin)О L(fng)U(xin)О ΣО L(fng)U(xin)ΣО S
science of blood donation service I(xin)Ѫ(w)W(xu) Ѫ(w)W(xu) Ѫ(w)W(xu) Ѫ(w)ƌW(xu) seroconversion ѪD(zhun)Q ѪD(zhun) ѪD(zhun) ѪD(zhun)Q serum grouping Ѫ嶨 Ѫ Ѫ嶨 o shelf life (ch)ڻЧ solid phase HLA antibody detection HLA wYxg(sh) HLA wzyg(sh) HLA wYxo
technology g(sh) standard operation procedure; SOP (bio)(zhn)Ҏ(gu) (bio)(zhn) (bio)(zhn) (bio)(zhn) sterile welding o۽ o۽ o۽ o T
therapeutic apheresis ίԆβ ίԷxg(sh) ίԆΒ o therapeutic dose ί ί ί o traceability of blood component ѪҺɷֿۙ ѪҺɷ֮ ѪҺɷֿ ۙѪҺɷ transfusion complications ݔѪl(f)Y ݔѪl(f)Y ݔѪl(f)Y ݔѪa(chn)F(xin)āl(f)Y transfusion management ݔѪW(xu) ݔѪ ݔѪ ݔѪ transfusion reactions ݔѪ(yng) ݔѪ(yng) ݔѪ(yng) ݔѪa(chn)F(xin)ķ(yng) transfusion technology ݔѪg(sh)W(xu) ݔѪg(sh) ݔѪg(sh)W(xu) ݔѪg(sh) transfusion-associated circulation overload; TACO ݔѪP(gun)ѭh(hun)ؓ(f) ݔѪP(gun)ѭh(hun)d ݔѪP(gun)ѭh(hun)ؓ(f) o transfusion-free medicine oݔѪt(y)W(xu) ݔѪt(y) ݔѪt(y)W(xu) ݔѪt(y)W(xu) transfusion-transmissible infection ɽ(jng)ݔѪĸȾ ɽ(jng)ݔѪĸȾ ɽ(jng)ݔѪĸȾ ^ݔѪȾĂȾ transfusion-transmitted bacterial infection; TTBI ݔѪļ(x)Ⱦ ݔѪļ(x)Ⱦ (jng)ݔѪļ(x)Ⱦ ^ݔѪȾļ(x)Ⱦ transfusion-transmitted infection; TTI ݔѪȾ ݔѪĸȾ (jng)ݔѪȾ ^ݔѪȾĂȾ U
unexpected antibody identification ⿹wb Ҏ(gu)t(A(y))wYz t(x)wwa o unexpected antibody screening ⿹wY Ҏ(gu)t(A(y))wYz t(x)wwYz o V
validation of blood establishment computer system ѪվϢϵy(tng)_J(rn) ѪC(j)(gu)YӍϵy(tng)(yn)C ѪҺYӍϵy(tng)_J(rn) ѪҺXϵy(tng)Ч_J(rn) validation _J(rn) (yn)C _J(rn) Ч_J(rn) W
window period մ մ մ
c(din)x